Shamburg News · 8-K filed Nov 12, 2026, 6:35 AM EST
Eikon Therapeutics Reports Third Quarter 2026 Results and Provides Clinical Updates
EIKN · Eikon Therapeutics, Inc.
- Earnings
- Leadership change
- Other event
- Materiality: high
Eikon Therapeutics furnished a press release reporting third quarter 2026 financial results and clinical updates, including ESMO 2026 data for its oncology programs. The company reported a Q3 2026 net loss attributable to common stockholders of $86.1 million, or $(1.59) per share, and cash, cash equivalents and marketable securities of $461.7 million as of September 30, 2026. Eikon also appointed Ching-Pin Chang as Chief Scientific Officer on September 3, 2026, and updated its cash runway guidance into the first quarter of 2028.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-456794.
Written from the filing by Shamburg Markets. Figures are as reported by the company.